Thomas Samuelson, MD
Ophthalmology · Minnetonka, MNNPI 1265427918
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $263,066 of the $434,719 with a category attached, or 60.5%. 15 manufacturers reported payments, led by Alcon at 38.6% of the total. Among ophthalmology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $1616.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$168K
- Glaukos Corporation$89K
- Alcon Research LLC$51K
- Sight Sciences, Inc.$38K
- Carl Zeiss Meditec, Inc.$25K
- AbbVie$20K
- plus $44K from 9 others
Across 20 payments — averaging $2296.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$35K
- Ivantis, Inc$8K
- Glaukos Corporation$2K
- Alcon Research LLC$750
What the payments were for
- Consulting fees$263,06661%
- Speaking & faculty fees$40,5519%
- Travel & lodging$5,5881%
- Food & beverage$11,3453%
- Education$1130%
- Gifts$2300%
- Other$113,82626%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 62 | $167,848 |
| Glaukos Corporation | 56 | $89,339 |
| Alcon Research LLC | 31 | $50,777 |
| Sight Sciences, Inc. | 26 | $37,579 |
| Carl Zeiss Meditec, Inc. | 19 | $24,826 |
| AbbVie(2 entities) | 29 | $20,253 |
| Ivantis, Inc | 21 | $17,866 |
| Aerie Pharmaceuticals, Inc. | 11 | $8,883 |
| Iridex Corporation | 1 | $5,000 |
| NEW World Medical,inc. | 4 | $4,539 |
| Bausch & Lomb Americas Inc. | 3 | $3,236 |
| Regeneron | 2 | $2,751 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $1,500 |
| Carl Zeiss Meditec USA, Inc. | 2 | $168 |
| Ocular Therapeutix, Inc. | 1 | $156 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$137,125
- iStent Trabecular Micro-Bypass Stent System$41,858
- iStent inject Trabecular Micro-Bypass Stent System$39,481
- OMNI(R) SURGICAL SYSTEM (US)$30,392
- SION SURGICAL INSTRUMENT$22,833
- Hydrus$15,101
- Rhopressa$13,802
- Rocklatan$13,683
- CIRRUS HD-OCT$12,825
- Voyager DSLT$12,500
- iStent inject W$12,486
- iStent$10,000
- VisuMax$9,075
- IOLMaster 700$9,000
- Travoprost Intraocular Implant - iDose$8,725
- CyPass$8,265
- OMNI$6,975
- XEN GLAUCOMA TREATMENT SYSTEM$5,988
- CALLISTO eye$5,325
- DURYSTA$5,249
How this compares
$434,719 in reported general payments places this provider in the 95th percentile of 330 ophthalmology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 213 | $106,953 |
| LumiganBimatoprost | 121 | $63,599 |
| RhopressaNetarsudil Mesylate | 119 | $54,872 |
| RestasisCyclosporine | 36 | $47,425 |
| VyzultaLatanoprostene Bunod | 84 | $35,550 |
| Latanoprost | 1,083 | $19,626 |
| Travoprost | 80 | $17,357 |
| XiidraLifitegrast | 13 | $17,130 |
| Brimonidine Tartrate | 242 | $16,107 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $13,787 |
| IyuzehLatanoprost/Pf | 19 | $13,599 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 40 | $12,427 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 45 | $12,417 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 591 | $11,985 |
| Bromfenac Sodium | 51 | $11,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $8,883 | $161,825332 claims |
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $20,253 | $136,124210 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $3,236 | $52,68097 claims |
| AlconSimbrinza | $167,848 | $12,42740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 330 ophthalmology providers in Minnesota.
Other ophthalmology in Minnetonka
- Edwin RyanMinneapolis$9.6M
- Mark LobanoffSt Louis Park$6.3M
- Richard LindstromBloomington$5.6M
- Deborah RistvedtAlexandria$392K
- Yun-Sen ChuBloomington$222K
- Sophie BakriRochester$183K
- David HardtenMinneapolis$119K
- John ChenRochester$82K
- Christine LarsenBloomington$70K
- Sandra MontezumaMinneapolis$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.